NEW YORK, NY / ACCESSWIRE / May 11, 2017 / U.S. markets were relatively quiet Wednesday as investors analyzed the latest batch of corporate earnings. Additionally, President Trump on Wednesday announced that he has dismissed FBI Director James Comey. The Dow Jones Industrial Average hit an intraday low of 20,884.15 before settling to close at 20,943.11, a decrease of 0.16 percent, while the S&P 500 Index hit an intraday low of 2,392.79 before settling to close at 2,399.63, an increase of 0.11 percent. As earnings season is coming to a close, investors now await data to provide a better picture of the health of the U.S. economy.

"A lot of us have Q2 significantly stronger. Economic data really needs to show they can support our forecasts," said Paul Christopher, head global market strategist for Wells Fargo Investment Institute.

RDI Initiates Coverage on:

MannKind Corp.
https://ub.rdinvesting.com/news/?ticker=MNKD

Neuralstem, Inc.
https://ub.rdinvesting.com/news/?ticker=CUR

MannKind's shares soared 42.86 percent to close at $1.60 a share on Wednesday. The stock traded between $1.16 and $1.88 on volume of 32.46 million shares traded. The company reported a net loss $16.3 million for the first quarter of 2017, compared to the net loss of $24.9 million in the first quarter of 2016. Total net revenue was $3.0 million for the first quarter, which was comprised of $1.8 million from the sale of surplus bulk insulin to a third party and $1.2 million of recognized Afrezza product sales. As of March 31st, 2017, Cash and cash equivalents were $48.0 million, compared to $22.9 million at the end of 2016. Shares of MannKind have fallen approximately 49.74 percent year-to-date.

Access RDI's MannKind Research Report at:
https://ub.rdinvesting.com/news/?ticker=MNKD

Neuralstem's shares spiked 36.52 percent to close at $4.00 a share on Wednesday. The stock traded between $3.12 and $4.18 on volume of 439,006 shares traded. The company reported a net loss of $7.6 million, or $0.68 per share, for the first quarter of 2017, compared to a loss of $6.6 million, or $0.93 per share, in the same quarter a year ago. Research and development totaled $2.9 million in the quarter. Cash, cash equivalents and short-term investments on hand was approximately $16.7 million at March 31, 2017, compared to approximately $20.2 million at December 31, 2016. Shares of Neuralstem have gained approximately 12.54 percent year-to-date.

"This is an exciting time for the company as we approach a large clinical milestone of NSI-189 Phase 2 major depressive disorder (MDD) study results, which remain ahead of schedule for the third quarter of this year," commented Rich Daly, chairman and CEO. "We also continue to strengthen our balance sheet and have extended our cash runway an additional quarter into late 2018."

Access RDI's Neuralstem Research Report at:
https://ub.rdinvesting.com/news/?ticker=CUR

Our Actionable Research on MannKind Corp. (NASDAQ: MNKD) and Neuralstem, Inc. (NASDAQ: CUR) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Hemal K. Gandhi, CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com